FTC Orange Book Move Signals New Pharma Patent Scrutiny
By Steve Albertson, Carl Morales and Erica Sutter · November 17, 2023, 3:44 PM EST
On Nov. 7, the Federal Trade Commission announced it is disputing the listing of more than 100 patents in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login